ris effektiv glykæmisk kontrol sammenlignet med subkutant indgivet hurtigtvirkende humant insulin.
Controlled clinical trials in type 1 or type 2 diabetes have shown that EXUBERA achieves and maintains effective glycaemic control comparable to subcutaneously administered fast-acting human insulin.